EP3962603A1 — Inhibitors of human immunodeficiency virus replication
Assigned to ViiV Healthcare UK No 5 Ltd · Expires 2022-03-09 · 4y expired
What this patent protects
The compounds depicted below, and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth (Formulae I or II).
USPTO Abstract
The compounds depicted below, and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth (Formulae I or II).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.